Avidity Biosciences, Inc. Stock Price, News & Analysis

Avidity Biosciences (NASDAQ: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three upcoming investor conferences in September 2025.

The management team will participate in fireside chats at the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley Global Healthcare Conference on September 8. Live webcasts and replays will be available on the company's investor relations website.

Avidity Biosciences (NASDAQ: RNA) reported significant progress in Q2 2025 across its key drug development programs. The company is preparing for three potential BLA submissions within a 12-month period, with its first commercial launch possible in 2026. Key highlights include FDA alignment on del-brax pathways for FSHD, positive Phase 1/2 FORTITUDE™ trial data, and planned del-zota BLA submission for DMD44 by year-end 2025.

Financially, Avidity maintains a strong position with $1.2 billion in cash and equivalents as of June 30, 2025, plus additional $185.5 million from ATM offering. Q2 2025 saw collaboration revenues of $3.8 million, while R&D expenses increased to $138.1 million and G&A expenses rose to $36.9 million. The company's cash runway extends to mid-2027, supporting global commercial launch preparations.

Avidity Biosciences (NASDAQ:RNA) has completed enrollment for HARBOR™, the first global Phase 3 trial of delpacibart etedesiran (del-desiran) for treating myotonic dystrophy type 1 (DM1). The company expects topline data in Q2 2026 and plans to submit marketing applications in the U.S., EU, and Japan starting in H2 2026.

Del-desiran, designed to address DM1's underlying genetic cause, has received multiple regulatory designations including Breakthrough Therapy, Orphan Drug, and Fast Track from the FDA. The HARBOR trial involves approximately 150 patients across 40 global sites, evaluating the drug's efficacy through various endpoints including video hand opening time (vHOT) and muscle strength measurements.

Avidity Biosciences (NASDAQ: RNA) has received FDA Breakthrough Therapy designation for delpacibart zotadirsen (del-zota) for treating Duchenne muscular dystrophy (DMD) in patients with mutations amenable to exon 44 skipping. The company is on track for BLA submission by end of 2025.

The Phase 1/2 EXPLORE44 trial demonstrated significant results, including statistically significant increases in exon skipping, substantial increase in dystrophin production, and significant reduction in creatine kinase levels to near normal. The company plans to present topline and functional data from the Phase 2 EXPLORE44-OLE trial in Q4 2025.

Del-zota has also received Orphan designation from FDA and EMA, plus Rare Pediatric Disease and Fast Track designations from FDA for DMD44 treatment.

Avidity Biosciences (NASDAQ: RNA) announced upcoming presentations of topline data from their Phase 1/2 FORTITUDE trial for del-brax (delpacibart braxlosiran) in facioscapulohumeral muscular dystrophy (FSHD) at the 32nd Annual FSHD Society International Research Congress in Amsterdam. The company has secured FDA alignment on both accelerated and full approval pathways for del-brax in FSHD treatment. Dr. Jeffrey M. Statland will present the trial's dose escalation data, while Dr. Stephen Tapscott will discuss findings on a novel DUX4-regulated circulating biomarker. The presentations include two oral sessions and one poster presentation scheduled for June 12-13, 2025.

Avidity Biosciences (RNA) announced positive topline data from Phase 1/2 FORTITUDE trial for delpacibart braxlosiran (del-brax) in treating Facioscapulohumeral Muscular Dystrophy (FSHD). Del-brax, the first therapy targeting the disease-causing DUX4 gene, showed consistent improvements in functional mobility, muscle strength, and quality of life compared to placebo. The trial evaluated 39 participants across two dose cohorts (2mg/kg and 4mg/kg) over 12 months. Key findings include improved 10-Meter Walk-Run test, Timed Up and Go, and quantitative muscle testing scores, along with significant reductions in KHDC1L and creatine kinase biomarkers. The company plans to submit a BLA for accelerated approval in H2 2026 and has initiated the Phase 3 FORWARD study. FSHD affects 45,000-87,000 people in the US and Europe, with no currently approved treatments.

Avidity Biosciences (RNA) announced that del-brax, its investigational therapy for facioscapulohumeral muscular dystrophy (FSHD), has received FDA clearance for the accelerated approval pathway. The company plans to submit a BLA in H2 2026 following topline data from the FORTITUDE biomarker cohort. Additionally, Avidity has initiated FORWARD, a global Phase 3 confirmatory study of del-brax 2mg/kg administered every six weeks in approximately 200 FSHD patients. Del-brax is the first therapy targeting DUX4, the disease-causing gene in FSHD, which affects 45,000-87,000 people in the US and Europe. The FORWARD study will evaluate functional mobility, strength, and patient-reported outcomes over 18 months. Currently, there are no approved treatments for FSHD, a rare hereditary disorder characterized by progressive muscle weakness and disability.

Avidity Biosciences (RNA) has granted equity-based inducement awards to 16 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The awards include 71,000 non-qualified stock options with an exercise price of $31.64 per share and 35,000 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. All awards are subject to continued employment and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for joining the company.

Avidity Biosciences (RNA) reported Q1 2025 financial results and progress across its clinical programs. The company maintains a strong financial position with $1.4 billion in cash, providing runway into mid-2027. Key highlights include positive topline del-zota data for DMD44 treatment, showing significant improvements in dystrophin production and creatine kinase levels. Avidity plans its first BLA submission by end of 2025. The company expects multiple Q2 updates for del-brax, including potential accelerated approval path and Phase 3 trial initiation. Financial results show collaboration revenues of $1.6 million (down from $3.5M in Q1 2024), R&D expenses of $99.5 million (up from $66.8M), and G&A expenses of $33.6 million (up from $13.9M). Avidity is preparing for potential commercial launches in 2026 while advancing three late-stage clinical programs.